scleroderma Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Languages supported at study center
Age Group

Any (9)

Phase 1/2 (1)
Phase 2 (1)
Unknown (7)

Observational (4)
Interventional (3)

Assistance Publique - Hôpitaux de Paris (1)
Institut National de la Santé Et de la Recherche Médicale, France (1)
National Taipei University of Nursing and Health Sciences (1)
National University, Singapore (1)
Topadur Pharma AG (1)
University Hospital, Bordeaux (1)
Yale University (1)

No (6)
Yes (3)

No (9)

All Languages (2)
English (2)
Arabic (1)
Argentinian Spanish (1)
Australian English (1)

Adult (18+) (9)
Pediatric (Under 18) (3)

I am/have/had

I am/have/hadprogressive systemic sclerosis

I am/have/hadscleroderma

I am/have/hadraynaud's syndrome

I am/have/hadraynaud disease

I am/have/hadrheumatism

I am/have/hadraynaud's phenomenon

I am/have/hadautoimmune disease

I am/have/hadfibrosis

I am/have/hadarthritis

I am/have/hadskin disease

I am/have/hadlupus

I am/have/hadmixed connective tissue disease

I am/have/hadsclerosis skin

I am/have/haddermatomyositis

I am/have/hadrheumatic diseases

I am/have/hadpulmonary involvement

I am/have/hadskin sclerosis

I am/have/hadmyositis

I am/have/hadsjogren's syndrome

I am/have/hadvasculitis

added new label for I am/have/had

more

I am looking for

I am looking forcorticosteroids

I am looking forimmunosuppressive agents

I am looking forcyclophosphamide

I am looking forprobe

I am looking forAccepts healthy volunteers

added new label for I am looking for

more

Advanced Filters

Loading...

Found 231 clinical trials

For Seniors
For adults
Recruiting in 10s
Observational Study
all
Dermatology
Recruiting

MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis

To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of systemic sclerosis.

cyclophosphamide

chest x-ray

pulmonary involvement

corticosteroids

skin sclerosis

0 views
16 Feb, 2024
1 location

19
20
21
22
23
24

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2026 All rights reserved.